Table 2. Univariate and mutivariate analysis for freedom-from progression (FFP), lymphoma-specific survival (LSS) and overall survival (OS).
| Variables | FFP | LSS | OS | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | |
| Univariate Analysis | |||||||||
| Bulky disease | 1.433 | 0.752–2.731 | 0.274 | 1.638 | 0.707–3.798 | 0.250 | 1.364 | 0.602–3.092 | 0.457 |
| B symptoms | 1.545 | 0.856–2.787 | 0.148 | 1.896 | 0.849–4.234 | 0.119 | 1.385 | 0.666–2.879 | 0.383 |
| Number of extranodal sites | 1.576 | 0.814–2.052 | 0.177 | 1.680 | 0.701–4.026 | 0.245 | 1.409 | 0.600–3.312 | 0.431 |
| Elevated LDH | 2.028 | 1.129–3.643 | 0.018 | 1.514 | 0.691–3.320 | 0.300 | 1.363 | 0.655–2.837 | 0.408 |
| IPS ≥ 3 | 2.798 | 1.541–5.082 | 0.001 | 2.494 | 1.120–5.554 | 0.025 | 2.099 | 1.007–4.373 | 0.048 |
| B2MG ≥ 2.5 mg/L | 3.483 | 1.797–6.750 | < 0.001 | 2.821 | 1.177–6.671 | 0.020 | 2.455 | 1.116–5.399 | 0.026 |
| Chemoradiotherapy | 1.117 | 0.621–2.009 | 0.712 | 1.327 | 0.593–2.967 | 0.491 | 1.059 | 0.507–2.212 | 0.879 |
| Mutivariate Analysis | |||||||||
| LDH | 1.082 | 0.542–2.157 | 0.824 | — | — | — | — | — | — |
| IPS ≥ 3 | 2.475 | 1.230–4.978 | 0.011 | 2.316 | 1.037–5.176 | 0.041 | 1.988 | 0.951–4.156 | 0.068 |
| B2MG ≥ 2.5 mg/L | 3.223 | 1.651–6.292 | 0.001 | 2.633 | 1.096–6.326 | 0.030 | 2.343 | 1.064–5.159 | 0.034 |
Note: HR = Hazard ratio, CI = confidence interval, LDH = lactate dehydrogenase, IPS: International Prognostic Score, B2MG: beta-2 microglobulin.